ALTSTATION.IO

Universal Health Services, Inc. (UHS) Stock Analysis

By Nova Skye | AltStation.io | Updated October 13, 2026

Price
$178.78
Change
-0.03%
Market Cap
$10.54B
Avg Volume
788.0K

Company Overview

Universal Health Services (UHS) is a healthcare provider based in King of Prussia, Pennsylvania, operating in the medical care facilities industry. Founded in 1978, the company runs two primary business lines: acute care hospitals and behavioral health facilities. Across its network of 30 acute care hospitals and 346 inpatient behavioral health centers, UHS delivers services ranging from emergency room care and general surgery to psychiatric treatment. Patients receive direct medical care, while private insurers and government programs like Medicare pay the bills. The company also sells commercial health insurance plans and hospital management services.

UHS is the clear market leader in behavioral health and an established challenger in acute hospital care. Its massive psychiatric network gives it scale and pricing power that traditional acute care operators cannot easily match. In acute care, UHS competes directly against larger operators like HCA Healthcare and Tenet Healthcare, while Acadia Healthcare is its main rival on the behavioral side. Rising clinical labor costs remain an ongoing operational threat, but the diversified mix between emergency care and psychiatric services provides dependable cash flow.

The business is currently expanding at a healthy clip on solid patient volumes. Full-year 2025 revenue reached $17.4 billion, a 9.7% increase year-over-year, followed by second-quarter 2026 revenue of $4.64 billion, up 8.3%. Management is backing that expansion with $950 million to $1.1 billion in planned 2026 capital expenditures for facility construction, renovations, and technology upgrades. That aggressive reinvestment rate shows UHS is focused on widening its footprint and locking down market share across both segments.

Key Financials
Market Cap
$10.54B
Revenue
$18.11B
EBITDA
$2.70B
Gross Margin
44.6%
Profit Margin
8.4%
Revenue Growth
8.3%
Total Cash
$138.80M
Total Debt
$5.26B
Free Cash Flow
$498.32M


52-Week Price Performance Analysis

Price Statistics
P/E Ratio
7.35
Forward P/E
7.48
Beta
1.03
52-Week High
$246.33
52-Week Low
$140.08
EPS
$24.32
50-Day Avg
$174.17
200-Day Avg
$179.34
Price/Book
1.40
UHS 52-Week Stock Chart
Technical Analysis
UHS trades at $178.78, 37% of the way from its exact 52-week low of $139.92 to its exact high of $245.26. The stock is 27.09% below that high and 27.81% above the low. Price is 0.90% above its 20-day moving average of $177.23, while momentum is positive at 1.58% over five trading days and 3.22% over 20 days. Near-term support is $167.49, and resistance is $181.39. The chart is improving, but UHS still needs to break $181.39 to strengthen the short-term trend.


Recent News and Developments

UHS spotlights Talkspace integration strategy

UHS published an October 12 update outlining plans to connect Talkspace’s virtual care with its outpatient and inpatient behavioral-health network. Talkspace adds approximately 6,000 licensed providers, but this is a strategy update rather than a new acquisition announcement. Source: Universal Health Services

UHS CEO lays out the Talkspace growth plan

CEO Marc Miller discussed using Talkspace’s technology to connect virtual therapy with UHS outpatient and inpatient services. The October 7 interview focused on building a broader behavioral-care network, not new financial guidance. Source: Yahoo Finance

Cantor Fitzgerald stays Neutral with a $194 target

Cantor Fitzgerald reiterated its Neutral rating and $194 price target on October 6. Acute-care openings worsened to 13.1% from 12.3%, while headcount growth slowed to 2% from 3% in the first quarter. Source: Investing.com



Market Sentiment and Analyst Recommendations

Bull Case
UHS generated $18.11 billion in revenue and is growing revenue at 8.3%. The stock trades at only 7.35 times earnings, a low valuation relative to that growth rate. The analyst consensus is buy across 17 analysts, with an average target of $194.94. That target sits $16.16 above the current $178.78 price. UHS is also building a connected behavioral-health network by combining Talkspace’s approximately 6,000 licensed providers with its outpatient and inpatient services. The stock’s positive five-day and 20-day momentum suggests buyers are starting to recognize the valuation gap.
Bear Case
UHS carries $5.26 billion in total debt against only $138.80 million in cash. That balance-sheet gap reduces flexibility if operating conditions deteriorate. Acute-care openings worsened to 13.1% from 12.3%, while headcount growth slowed to 2% from 3% in the first quarter. The stock remains 27.09% below its 52-week high, showing that the market has not fully bought into the recovery. Cantor Fitzgerald’s Neutral rating and $194 target also show that not every analyst sees a strong buying opportunity. The broader analyst target range runs as low as $166.00, below both the current price and the $167.49 near-term support level.
What to Watch
The first technical test is $181.39, the 30-day high and immediate resistance level. A sustained move above that price would strengthen the current positive momentum, while a decline below the $177.23 moving average would weaken it. The larger downside threshold is $167.49, the 30-day low and near-term support. Investors should watch whether acute-care openings improve from 13.1% and whether headcount growth recovers from 2%. UHS also needs to show concrete progress connecting Talkspace’s approximately 6,000 licensed providers with its outpatient and inpatient network. The October 7 interview and October 12 update described the strategy but provided no new financial guidance, so measurable operating results are the next proof point.
Analyst Consensus
BUY

Based on 17 analyst opinions
Low Target
$166.00
Mean Target
$194.94
High Target
$290.00


Earnings and Financial Data

Sector
Healthcare
Industry
Medical Care Facilities
Employees
102,000
Earnings & Dividends
Next Earnings
Oct 27, 2026
EPS (Trailing)
$24.32
Dividend Yield
45.0%
Payout Ratio
3.3%

Frequently Asked Questions

Is UHS a good stock to buy?
The analyst recommendation is buy based on 17 analysts, and UHS trades at a P/E of 7.35 while revenue is growing 8.3%. The takeaway is that the valuation and growth data support the buy case, but the recommendation is not unanimous price certainty.
What is UHS’s price target?
The average analyst target is $194.94, with estimates ranging from $166.00 to $290.00. The takeaway is that the average target is above the current $178.78 price, but analyst expectations vary widely.
How far is UHS below its 52-week high?
UHS is 27.09% below its exact 52-week high of $245.26. The takeaway is that the stock has substantial distance to recover before returning to its yearly peak.
What are the support and resistance levels for UHS?
Near-term support is the 30-day low of $167.49, while resistance is the 30-day high of $181.39. The takeaway is that these are the key levels framing the current $178.78 price.
Does UHS pay a dividend?
The provided data does not include dividend information. The takeaway is that no dividend conclusion can be made from these figures alone.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 13, 2026.